APA (7th ed.) Citation

Boch, T., Luft, T., Metzgeroth, G., Mossner, M., Jann, J., Nowak, D., . . . Nolte, F. (2018). Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS. Leukemia research, 68, . https://doi.org/10.1016/j.leukres.2018.03.007

Chicago Style (17th ed.) Citation

Boch, Tobias, et al. "Safety and Efficacy of the CD95-ligand Inhibitor Asunercept in Transfusion-dependent Patients with Low and Intermediate Risk MDS." Leukemia Research 68 (2018). https://doi.org/10.1016/j.leukres.2018.03.007.

MLA (9th ed.) Citation

Boch, Tobias, et al. "Safety and Efficacy of the CD95-ligand Inhibitor Asunercept in Transfusion-dependent Patients with Low and Intermediate Risk MDS." Leukemia Research, vol. 68, 2018, https://doi.org/10.1016/j.leukres.2018.03.007.